| Tumour Group / Site |
| Trial Title | Opening Date |
|---|
Breast
| | A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-postive unresectable locally advanced or metastatic breast cancer
(Syneos Tulip)
| 29Jul2019
|
| | A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
(CCTG MA.39)
| 1May2019 |
| | A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)
(AstraZeneca Violette) | Sept 2018
|
| | A DOUBLE-BLIND, PLACEBO-CONTROLLED,RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST
(Roche CO40016 Ipatunity 130) | 16Apr2018
|
| | PALbociclib CoLlaborative Adjuvant Study: A
randomized phase III trial of Palbociclib with standard adjuvant endocrine
therapy versus standard adjuvant endocrine therapy alone for hormone receptor
positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early
breast cancer
(MA37 PALLAS)
| 22Nov2017 |
| | Partial breast irradiation using interstitial permanent Pd 103 seed implant
(PBSI-Radiation) | May
2012 |
CNS
| |
| |
GI
| | A phase II/III trial of Neoadjuvant Folfox, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients cancer patients undergoing low anterior resection with total mesorectal excision.
(NCIC CRC.7) | April
2014
|
| GU - Bladder | | A Phase 3 Study of Erdafitinib Compared With
Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial
Cancer and Selected FGFR Gene Aberrations
(Janssen THOR)
| Jan 2018
|
| GU- Prostate | | A Phase 2 Study of Nivolumab in Combination with
Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant
Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb
clinical Trial Evaluation 9KD)
(BMS CA209-9KD)
| Nov 2018
|
| | HDR Partial Prostate Brachytherapy as Salvage Treatment for Local Failures After Previous External Beam Radiotherapy
(HDR Salvage-radiation)
| 2018 |
| | A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal
(AstraZeneca Profound)
| 12Oct2017 |
| | A Phase III Randomized Study of Low Dose Rate compared to High Dose Rate Prostate Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
(Monotherapy)
| |
| | A PHASE II STUDY OF DURVALUMAB (MEDI4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
(IND 232 CCTG)
| 18Apr2017
|
| | Improving quality of life (QOL) after optimal radiotherapy for intermediate and high risk prostate cancer: HDR vs. LDR brachytherapy boost
(QOL-radiation)
| December
2013
|
| GU - Kidney | | A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
(EISAI E7080-G000-218 Hope)
| 4Jul2018
|
| | A Phase III, multicenter, randomized Placebo-Controlled, Double-blind study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy.
(Roche W039210)
| March
2018
|
| GU - Multi | | | |
Gyne | | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First Line treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (KEYNOTE 826) | 14May2019
|
Lung
| | A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer
(MERCK ECHO)
| Currently on hold
7Mar2018
|
| | A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA
(IND227 CCTG) | 16Feb2017
|
| Lymphoma | |
|
|
| Multiple Myeloma | | | |
Melanoma | | A Phase 3 Randomized,
Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib
(E7080/MK-7902) Versus Pembrolizumab Alone as First-line
Intervention in Participants With Advanced Melanoma
(Merck MK-7902-003 / LEAP-003)
| 29Jul2019
|
| Multi-site (endometrial, squamous cell, ovarian, breast, non-small cell lung) | | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
(Tesaro Garnet)
| 8Nov2017
|
| | Phase II non-randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastases
(SABR-radiation)
| 1Jan2017
|
Supportive / Palliative Care
| |
|
|
